|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Current assets: | |||||||||
| Cash and cash equivalents | |||||||||
| Restricted cash | |||||||||
| Property and equipment held for sale | |||||||||
| Short-term investments | |||||||||
| Accounts receivable - collaboration agreement | |||||||||
| Prepaid expenses | |||||||||
| Operating lease right of use assets, current | |||||||||
| Other current assets | |||||||||
| Total current assets | |||||||||
| Other assets, noncurrent | |||||||||
| Operating lease right of use assets | |||||||||
| Property and equipment, net | |||||||||
| Total assets | |||||||||
| Liabilities and stockholders' equity | |||||||||
| Current liabilities: | |||||||||
| Accounts payable | |||||||||
| Accrued expenses and other current liabilities | |||||||||
| Operating lease liability, current | |||||||||
| Deferred revenue, current | |||||||||
| Total current liabilities | |||||||||
| Deferred revenue, noncurrent | |||||||||
| Operating lease liability, noncurrent | |||||||||
| Other liabilities, noncurrent | |||||||||
| Total liabilities | |||||||||
| Preferred stock ,shares authorized, issued and outstanding | |||||||||
| Series A Preferred Stock | |||||||||
| Series A redeemable convertible preferred stock | |||||||||
| Series B-1 redeemable convertible preferred stock | |||||||||
| Series B-2 redeemable convertible preferred stock | |||||||||
| Series C Preferred Stock | |||||||||
| Series D Preferred Stock | |||||||||
| Series C redeemable convertible preferred stock | |||||||||
| Series D redeemable convertible preferred stock | |||||||||
| Total preferred stock ,shares authorized, issued and outstanding | |||||||||
| Stockholders' equity | |||||||||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized at June 30, 2025 and December 31, 2024, respectively, 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | |||||||||
| Common stock, $0.001 par value; 490,000,000 shares authorized at June 30, 2025 and December 31, 2024, respectively, 23,140,691 and 23,136,617 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | |||||||||
| Additional paid-in capital | |||||||||
| Accumulated other comprehensive loss | |||||||||
| Accumulated deficit | |||||||||
| Total stockholders' equity | |||||||||
| Total liabilities and stockholders' equity |
Loading...
